Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).

Trial Profile

Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Jan 2018

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Renal failure; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms BEACON
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 18 Jan 2018 Results published in a Reata Pharmaceuticals media release
    • 18 Jan 2018 According to a Reata Pharmaceuticals Media Release, post-hoc analyses presented in the American Journal of Nephrology.
    • 14 Nov 2016 According to a Reata Pharmaceuticals Media Release, based on the data of an analysis assessing risk factors and its risk mitigation strategy for managing acute fluid retention of this trial, FDA approved the Phase 2 program in PAH (LARIAT)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top